Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas.
Case histories of 61 patients receiving multimodality therapy for primary malignant brain tumors were reviewed for factors visible on the computerized tomography (CT) scan that correlated with the interval of time from diagnosis and pretherapy evaluation to the time of documented tumor progression. The initial pretreatment CT scan of each patient was reviewed. Midline shift, peritumor low density (edema), the greatest diameter of tumor enhancement, and the greatest diameter of the intratumor low-density area were measured prior to radiation therapy and chemotherapy. Using a Weibull survival probability model, time to tumor progression was most satisfactorily fitted using two covariates, the volume of enhancing tumor (for instance, contrast-enhancing tumor less intratumor low density), and the presence of a peritumor low-density area. Patients who exhibited a small amount of contrast-enhancing tumor with peritumor low density tended to have a longer time to progression than patients with large contrast-enhancing tumor volume and no peritumor low density. Midline shift was not as important a variable as the extent of tumor contrast enhancement or peritumor low density.
D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D005910:Glioma / Q000000981:diagnostic imaging* / Q000628:therapy; D006801:Humans; D011379:Prognosis; D014057:Tomography, X-Ray Computed